Due to its unique design, DRhQ can bind to and inhibit both T cell receptors and the MHC “invariant” chain, CD74, that serves as the receptor for the proinflammatory homologs, MIF and MIF2, resulting in blockade of multiple contributors to the Cytokine Storm.